Search results for "survival analysi"

showing 10 items of 752 documents

<title>Multiparameter breast cancer cell image analysis for objective estimation of nuclear grade: comparison with light microscopic observatio…

2000

We performed a multi parameter image analysis assessment of breast cancer cell population nuclear grade (NG), which is regarded as one of the main prognostic factors for treatment efficacy and survival of the patients and compared it with light microscopic estimation of NG. Cytological imprint slides from 20 ductal carcinomas were stained according to Leischmann-AzureII-eosine method, and NG was estimated by light microscopic observation according to Black in Fisher's modification. Simultaneously, using specially elaborated software, in each patient 100 cancer cells were analyzed for nuclear perimeter, diameter, area, nucleolar area, and average intensity of staining. The chromatin structur…

Pathologymedicine.medical_specialtyeducation.field_of_studymedicine.diagnostic_testbusiness.industryPopulationMammary glandCancermedicine.diseaseCell nucleusBreast cancerFine-needle aspirationmedicine.anatomical_structureCancer cellMedicinebusinessNuclear medicineeducationSurvival analysisSPIE Proceedings
researchProduct

Interspecific differences in carotenoid content and sensitivity to UVB radiation in three acanthocephalan parasites exploiting a common intermediate …

2011

9 pages; International audience; Few endoparasite species are pigmented. Acanthocephalans are an exception however, with several species being characterised by yellow to orange colouration both at the immature (cystacanth) and adult stages. However, the functional and adaptive significance of carotenoid-based colourations in acanthocephalans remains unclear. One possibility is that the carotenoid content of acanthocephalan cystacanths acts as a protective device against ultra-violet radiation (UVR) passing through the translucent cuticle of their crustacean hosts. Indeed, acanthocephalans often bring about behavioural changes in their aquatic intermediate hosts that can increase their expos…

Pigments[ SDV.MP.PAR ] Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyUltraviolet RaysPomphorhynchusAcanthocephalachemistry.chemical_compoundAstaxanthinBotany[ SDV.EE.IEO ] Life Sciences [q-bio]/Ecology environment/SymbiosisAnimalsAmphipodaCarotenoidchemistry.chemical_classification[ SDE.BE ] Environmental Sciences/Biodiversity and EcologyAdaptive colourbiologyPhotoprotectionIntermediate hostfood and beveragesbiology.organism_classificationCarotenoidsSurvival AnalysisPolymorphusPolymorphusGammarus pulexInfectious DiseaseschemistryPhotoprotectionParasite manipulationParasitologyPomphorhynchus laevisAcanthocephala
researchProduct

The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep

2020

The Essential Thrombocythemia is a Chronic Philadelphia-negative Myeloproliferative Neoplasm characterized by a survival curve that is only slightly worse than that of age- and sex-adjusted healthy population. The criteria for diagnosis were reviewed in 2016 by WHO. The incidence varies from 0.2 to 2.5:100 000 people per year, with a prevalence of 38 to 57 cases per 100 000 people. The main characteristics of ET are the marked thrombocytosis and the high frequency of thrombosis. The spectrum of symptoms is quite wide, but fatigue results to be the most frequent. Thrombosis is frequently observed, often occurring before or at the time of diagnosis. The classification of thrombotic risk has …

Plateletsmedicine.medical_specialtylcsh:RC633-647.5Essential thrombocythemiabusiness.industryPlateletlcsh:Diseases of the blood and blood-forming organsHematologyReviewMyeloproliferative Neoplasmmedicine.diseaseGastroenterology03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisDigInternal medicinemedicineMyeloproliferative NeoplasmsThrombocythemiabusinessSurvival analysisMyeloproliferative neoplasm030215 immunologySlightly worse
researchProduct

Bortezomib Partially Improves Laminin α2 Chain–Deficient Muscular Dystrophy

2014

Congenital muscular dystrophy, caused by mutations in LAMA2 (the gene encoding laminin α2 chain), is a severe and incapacitating disease for which no therapy is yet available. We have recently demonstrated that proteasome activity is increased in laminin α2 chain-deficient muscle and that treatment with the nonpharmaceutical proteasome inhibitor MG-132 reduces muscle pathology in laminin α2 chain-deficient dy(3K)/dy(3K) mice. Here, we explore the use of the selective and therapeutic proteasome inhibitor bortezomib (currently used for treatment of relapsed multiple myeloma and mantle cell lymphoma) in dy(3K)/dy(3K) mice and in congenital muscular dystrophy type 1A muscle cells. Outcome measu…

Proteasome Endopeptidase ComplexApoptosisBiologyPathology and Forensic MedicineBortezomibmedicineAnimalsMyocyteMuscular dystrophyCells CulturedMultiple myelomaMuscle CellsMyogenesisBortezomibMusclesBody WeightMuscular Dystrophy Animalmedicine.diseaseBoronic AcidsFibrosisSurvival AnalysisMice Inbred C57BLDisease Models AnimalMicroRNAsGene Expression RegulationOrgan SpecificityPyrazinesCongenital muscular dystrophyCancer researchProteasome inhibitorMantle cell lymphomaLamininLocomotionmedicine.drugThe American Journal of Pathology
researchProduct

Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer

2009

Abstract Purpose: We studied the expression levels of cyclins B1, D1, and E1 and the implications of cyclin overexpression for patient outcomes in distinct breast cancer subtypes defined by clinical variables and transcriptional profiling. Experimental Design: The expression levels of cyclins B1, D1, and E1 were quantified in 779 breast tumors and 53 cell lines using reverse phase protein arrays and/or transcriptional profiling. Results: Whereas cyclin E1 overexpression was a specific marker of triple-negative and basal-like tumors, cyclin B1 overexpression occurred in poor prognosis hormone receptor–positive, luminal B and basal-like breast cancers. Cyclin D1 overexpression occurred in lum…

ProteomicsCancer ResearchPathologymedicine.medical_specialtyCyclin EClass I Phosphatidylinositol 3-KinasesCyclin DDNA Mutational AnalysisCyclin BBreast NeoplasmsBiologyCyclin BArticlePhosphatidylinositol 3-KinasesCyclin D1Predictive Value of TestsCell Line TumorCyclin Emedicine1-Phosphatidylinositol 3-KinaseHumansCyclin D1BreastCyclin B1Cyclin B1Oligonucleotide Array Sequence AnalysisProportional Hazards ModelsOncogene ProteinsGene Expression ProfilingCancermedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisGene Expression Regulation NeoplasticCyclin E1OncologyReceptors EstrogenSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationMutationCancer researchbiology.proteinFemaleBreast diseaseReceptors Progesterone
researchProduct

Expression of B-Cell Activating Factor Enhances Protective Immunity of a Vaccine against Pseudomonas aeruginosa

2009

ABSTRACT B-cell activating factor (BAFF), a member of the TNF family, is a potent cytokine with stimulatory effects on B and T cells. To evaluate the potential of transient overexpression of BAFF to enhance vaccine immunogenicity, a replication-deficient adenovirus expressing full-length murine BAFF (AdBAFF) was tested in a mouse vaccine model against Pseudomonas aeruginosa . When coadministered with heat-killed P. aeruginosa , AdBAFF mediated a significant increase in anti- P. aeruginosa- specific serum and lung mucosal antibodies and resulted in improved protection against a lethal respiratory challenge with P. aeruginosa . This effect was independent of the site of administration of AdBA…

Pseudomonas Vaccinesmedicine.medical_treatmentGenetic VectorsImmunologyBiologymedicine.disease_causeMicrobiologyAdenoviridaeMicrobiologyMiceImmune systemAdjuvants ImmunologicImmunityB-Cell Activating FactorPneumonia BacterialmedicineAnimalsB-cell activating factorImmunity MucosalPseudomonas aeruginosaAntibodies BacterialSurvival AnalysisMice Inbred C57BLInfectious DiseasesCytokineVaccines InactivatedImmunizationMicrobial Immunity and VaccinesPseudomonas aeruginosaImmunologybiology.proteinFemaleParasitologyAntibodyAdjuvantInfection and Immunity
researchProduct

Retrograde in situ versus antegrade pulmonary preservation in clinical lung transplantation: a single-centre experience.

2014

OBJECTIVE Experimental and clinical studies have indicated a beneficial effect of retrograde lung preservation on post-transplant results. Accordingly, we conducted a non-randomized trial. METHODS A total of 209 consecutive recipients transplanted with low-potassium dextrane (LPD)-preserved lungs were eligible for analysis. Antegrade lung preservation (AP) was performed in 173 patients and retrograde in situ perfusion (RP) in 36 patients using low-potassium dextrane solution in all cases. The prostacycline was added to preservation solution. RESULTS The main donor, graft and recipient characteristics did not differ significantly between groups. There was a beneficial trend toward improved o…

Pulmonary and Respiratory MedicineAdultGraft RejectionMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentOrgan Preservation SolutionsUrologyPrimary Graft DysfunctionBronchiolitis obliteransKaplan-Meier Estimate030204 cardiovascular system & hematologyRisk AssessmentStatistics NonparametricCohort Studies03 medical and health sciences0302 clinical medicinemedicineLung transplantationHumansProportional Hazards ModelsRetrospective StudiesLungbusiness.industryIncidence (epidemiology)Graft SurvivalGeneral MedicineOxygenationOrgan PreservationMiddle Agedmedicine.diseaseSurvival AnalysisTissue DonorsTransplantationmedicine.anatomical_structureTreatment Outcome030228 respiratory systemCohortMultivariate AnalysisSurgeryFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesLung TransplantationEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
researchProduct

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): A multicentre phase II clinical trial

2001

Abstract A phase II study in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) was carried out to evaluate the clinical activity and toxicity of the chemotherapeutic combination of gemcitabine+vinorelbine (GEM/VNR). Forty-five patients (40 male, 5 female) with a median age of 67 years (range 37–73) and a median ECOG performance status of 1 (range 0–2) were enrolled into the trial. Twenty patients had stage IIIB (two positive supraclavicular nodes and 20 cytologically positive pleural effusion), and 25 had stage IV NSCLC. GEM 1000 mg/m 2 diluted in 250 cc 3 of normal saline was administered iv on days 1, 8, and 15, while VNR was given 30 mg/m 2 on days 1 and 8 every 4 weeks. The…

Pulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaPleural effusionmedicine.drug_classnon-small cell lung cancer (NSCLC)Phases of clinical researchNeutropeniaVinorelbineVinblastineGastroenterologyAntimetaboliteDeoxycytidineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousAgedbusiness.industryVinorelbineMiddle Agedmedicine.diseaseSurvival AnalysisGemcitabineGemcitabineSurgeryRegimenTreatment OutcomeOncologyInjections IntravenousFemalebusinessmedicine.drug
researchProduct

Value of echocardiography in patient follow-up after surgically corrected type A aortic dissection.

2001

Background To identify patients (pts) at risk of late complications, follow-up after surgery for type A aortic dissection is essential. We assessed the value of echocardiography to monitor patients after surgery for type A aortic dissection. Methods 80 out of 108 pts operated between 1989 and 1999 for type A aortic dissection survived surgery. 62 pts with at least one TEE, CT or MRI examinations during follow-up were included in this study. All pts had transthoracic echocardiography (TTE), 53 transesophageal echocardiography (TEE), 51 had CT, and 39 had MRI. Results At the first follow-up, 12 of 48 pts with aortic valve sparing surgery presented with aortic insufficiency >I degrees detected…

Pulmonary and Respiratory MedicineAortic archAortic valveAdultMaleReoperationmedicine.medical_specialtyTime FactorsAortic Valve InsufficiencySeverity of Illness IndexDiagnosis DifferentialAortic aneurysmAneurysmmedicine.arteryGermanymedicineHumansAgedAortic dissectionAged 80 and overPostoperative Caremedicine.diagnostic_testbusiness.industryMagnetic resonance imagingStroke VolumeStroke volumeMiddle Agedmedicine.diseaseImage EnhancementMagnetic Resonance ImagingSurvival AnalysisAortic AneurysmAortic Dissectionmedicine.anatomical_structureEchocardiographyAortic Valvecardiovascular systemDisease ProgressionSurgeryFemaleRadiologyDifferential diagnosisCardiology and Cardiovascular MedicinebusinessTomography X-Ray Computedhuman activitiesFollow-Up StudiesThe Thoracic and cardiovascular surgeon
researchProduct

A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC)

2006

Introduction: Lung cancer is the leading cause of tumour-related deaths in the elderly population but the optimal management of advanced NSCLC in older patients has not been defined to date. The present phase II study was planned to evaluate the efficacy and toxicity of the combination of carboplatin and paclitaxel in elderly patients with advanced NSCLC. Patients and methods: Patients (>70 years old) who had pathologically been proven to have a NSCLC and measurable lesions were treated with paclitaxel (175 mg/m2for 3 h) and carboplatin [area under the concentration-time curve (AUC = 5)] on day 1 every 3 weeks. Results: Forty patients were enrolled into the study. The median age was 74 year…

Pulmonary and Respiratory MedicineMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPopulationnon-small cell lung cancer (NSCLC)Phases of clinical researchNeutropeniaGastroenterologyCarboplatinchemistry.chemical_compoundElderlyNon-small cell lung cancerInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancereducationAgededucation.field_of_studyChemotherapyAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industrymedicine.diseaseSurvival AnalysisCarboplatinSurgeryLung NeoplasmTreatment OutcomeOncologychemistryItalyCarboplatin plus paclitaxelFemaleSurvival AnalysibusinessHuman
researchProduct